Akero Therapeutics

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Our mission is to accelerate the discovery, development and delivery of breakthrough therapies to address unmet medical needs. We pursue innovation and collaboration to develop transformative treatments in areas with significant unmet need.

Our vision is to be a leader in the development of cutting-edge therapies that offer transformative potential for patients with life-threatening and chronic diseases.

Akeron Therapeutics has been recognized as a top player in the biopharma industry by numerous awards, including the Scrip Award for Breakthrough Therapy, the Frost & Sullivan Award for Most Promising Emerging Biotechnology Company and the Endeavor Award for Fastest Growing Biotech Company.